Change in management
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts less than Nifty Microcap 250 and 0.1 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
At a board meeting on 30 May 2025, Bandaram Pharma Packtech approved audited FY25 results, recommended a final dividend of Re. 0.10 per share, and appointed new internal auditors (M/s MGR & Co.) and secretarial auditors (M/s Manoj Parakh & Associates for 5 years). Independent Director Mr. Venkata Subramanya Rajaram Chittuluru resigned citing business commitments, and Mr. Prateek Vijayvargiya was appointed as a new Independent Director for a 5-year term, also taking over as Chairperson of all three key board committees. On the numbers, consolidated revenue rose to Rs. 3,696.37 lakh (vs Rs. 3,407.89 lakh) with net profit of Rs. 99.38 lakh (vs Rs. 94.77 lakh), while standalone revenue fell to Rs. 1,222.83 lakh and the company slipped to a small net loss of Rs. 1.66 lakh. The auditor flagged governance concerns: 57.79% of holding company sales and 35.99% of purchases were with its own subsidiary, and Rs. 1,959.74 lakh of debtor/creditor balances were adjusted via book entries without actual cash movement.
Routine board-level housekeeping, but the standalone loss and the auditor's red flags around heavy related-party dealings and large book-entry adjustments are worth watching closely. The tiny Re. 0.10 dividend is largely symbolic, and the stock is unlikely to react meaningfully on management reshuffle alone.